WHAT IS ANDOSAN?
AndoSan™ is extracted from three different mushrooms, where Agaricus blazei Murill represents the dominating one. AbM is grown from a secret Agaricus strain – stored at two different geographic locations in Japan
HOW CAN IMMUNOPHARMA HELP?
Extracts from Agaricus are prepared using various mushroom strains, diverse formulas and in accordance to different protocols; and therefore not all of them exhibit similar properties.
AndoSan™, produced in Japan, is GMP (Good Manufacturing Practices) certified. Its complex and time-consuming production process guarantees a formula that is effective, safe and consistent. Recently conducted independent scientific comparisons revealed that AndoSan™ is the most promising amongst commercially available products; and this particular mushroom extract was chosen for further studies – in both animal and clinical models.
Product extracted from a mixture of three different mushrooms
Anti-inflammatory, anti-allergic and anti-cancer effects
The product has substantially been upgraded until emerging as the current AndoSan™
Agaricus blazei Murill is an edible, medicinal mushroom with characteristic, somewhat sweet taste and the fragrance of almonds, that has traditionally been used against a wide range of diseases, including cancer, chronic hepatitis and diabetes
It’s also known under the names of Almond mushroom, Cogumelo de Sol, da Vida or de Deus (mushroom of the Sun, Life and God) in Brazil or Himematsutake (princess matsutake) in Japan.
Initializing basic research in the Norwegian Institute of Public Health
AndoSan™ was chosen as the most promising Agaricus extract based on cellular and anti-infection studies in mice
AndoSan™ was found to protect against deadly bacterial infections in mice
AndoSan™ was shown at Oslo University Hospital (OUS), Norway to influence genes that are important for immune and cancer defense
Doctoral thesis at OUS Possible follow-up studies/use of AndoSan™ on patients with serious multi-drug-resistant hospital infections
Anti-allergic effect of AndoSan™ – shown both on preventive and curative mouse model
Anti inflammatory effect of AndoSan™ established in healthy Norwegian volunteers and confirmed in patients with the autoimmune inflammatory bowel diseases; ulcerative colitis and Crohn’s disease
A clinical tendency to increased regression free survival is observed in a trial in patients with blood cancer (multiple myeloma) at OUS. Published 2015
A carbohydrate fraction of AndoSan™ inhibiting the activity of the cancer promoting enzyme legumain was identified and formed the basis for a US patent application
Study in a mouse model of colorectal cancer resulted in 60% reduction in tumor load in the AndoSan™ group compared to the control group. Published 2017
Results from a clinical study on a toptal of 100 patients with ulcerative colitis (50) or Crohn’s disease (50) shows improvements in physical function and quality of life in the AndoSan™ groups
Promising preliminary results from a clinical trial on patients with allergy and/or asthma. Expected publications 2017/18
Learn more about our productSee more